What Are Research Peptides? A Primer

“Peptide” gets used loosely, so it’s worth starting with a precise definition before getting into sourcing or handling. A peptide is a short chain of amino acids linked by peptide (amide) bonds — chemically identical to the bonds that build proteins, just far fewer of them. The conventional (if slightly fuzzy) cutoff is that chains under roughly 50 amino acids are called peptides, and longer chains are called proteins. BPC-157, for instance, is 15 amino acids long; a protein like insulin’s A and B chains together run 51.

Where peptides sit in biology

Many peptides function as signaling molecules — they bind to specific receptors and trigger a downstream response, the same basic mechanism used by hormones. This is why peptide research spans such a wide range of biological systems: growth factor pathways, metabolic regulation, tissue repair signaling, and neuroendocrine function all involve peptide signaling at some level. GLP-1 itself is a peptide hormone, originally studied for its role in insulin secretion long before GLP-1 receptor agonists became a major research area in metabolic science.

How research peptides are made

Nearly all research peptides today are produced by solid-phase peptide synthesis (SPPS), a method developed by Bruce Merrifield in the 1960s (work that earned him the 1984 Nobel Prize in Chemistry). The core idea: build the chain one amino acid at a time on an insoluble resin support, so that after each coupling step, excess reagents can simply be washed away rather than requiring purification of an intermediate in solution.

The process, at a high level:

1. Anchor the first (C-terminal) amino acid to a resin bead, with reactive groups temporarily protected.
2. Deprotect the amino group so the next amino acid can attach.
3. Couple the next protected amino acid, forming a new peptide bond.
4. Repeat steps 2–3 for each residue in the sequence, building the chain from C-terminus to N-terminus.
5. Cleave the finished chain from the resin and remove remaining protecting groups.
6. Purify, typically via HPLC, to isolate the target sequence from truncated or deletion side-products that inevitably form during synthesis.
7. Lyophilize the purified peptide into a stable powder for storage and shipping.

Longer sequences and those with difficult secondary structure (aggregation-prone regions, multiple cysteines requiring disulfide formation) are harder to synthesize cleanly, which is part of why purity and price both tend to scale with sequence length and complexity.

Peptides vs. small molecules vs. proteins

• Small-molecule drugs (aspirin, most traditional pharmaceuticals) are typically under 1,000 Da, chemically simple, and often orally bioavailable.
• Peptides sit in the middle — larger and more specific in their target interactions than small molecules, but far simpler to synthesize and characterize than full proteins. Most are not orally bioavailable due to digestive breakdown, which is why research applications typically involve injectable or topical delivery.
• Proteins (antibodies, enzymes, growth hormone) are produced recombinantly in living cells rather than synthesized chemically, because their length and folding complexity exceed what SPPS can reliably build.

Why the synthesis method matters to a buyer

Two vials both labeled “BPC-157, 99% purity” can come from meaningfully different synthesis and purification processes, and that difference shows up in things a label doesn’t capture: how much truncated-sequence byproduct remains, how consistent purity is batch to batch, and how well the peptide holds up in storage. This is the practical reason COAs and lot-specific testing matter more in this field than in most consumer product categories — the manufacturing process has real variability, and the only way to know what you’re getting is to look at the data for that specific batch.

Understanding the basic chemistry doesn’t require a synthesis background. But it does explain why “purity,” “lot testing,” and “cold chain” keep coming up as the load-bearing concepts in sourcing decisions — they’re not marketing language, they’re the direct downstream consequences of how these molecules are actually built.